Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2007;50:919-925
Published online before print September 10, 2007, doi: 10.1161/HYPERTENSIONAHA.107.093450
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
50/5/919    most recent
HYPERTENSIONAHA.107.093450v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sartório, C. L.
Right arrow Articles by Bauersachs, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sartório, C. L.
Right arrow Articles by Bauersachs, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Attack
Hazardous Substances DB
*SPIRONOLACTONE
Related Collections
Right arrow Acute myocardial infarction
Right arrow Endothelium/vascular type/nitric oxide
Right arrow ACE/Angiotension receptors
Right arrowRelated Article

(Hypertension. 2007;50:919.)
© 2007 American Heart Association, Inc.


Original Articles

Mineralocorticoid Receptor Blockade Improves Vasomotor Dysfunction and Vascular Oxidative Stress Early After Myocardial Infarction

Carmem Luíza Sartório; Daniela Fraccarollo; Paolo Galuppo; Meike Leutke; Georg Ertl; Ivanita Stefanon; Johann Bauersachs

From the Medizinische Klinik und Poliklinik I (C.L.S., D.F., P.G., M.L., G.E., J.B.), Universitätsklinikum Würzburg, Bayerische Julius-Maximilians-Universität Würzburg, Germany; and the Department of Physiological Sciences (C.L.S., I.S.), Federal University of Espírito Santo, ES, Brazil.

Correspondence to Johann Bauersachs, MD, Medizinische Klinik I, Universitätsklinikum 1, Julius-Maximilians-Universität, Josef-Schneider-Str. 2, 97080 Würzburg, Germany. E-mail bauersachs_j{at}medizin.uni-wuerzburg.de

Mineralocorticoid receptor blockade improves mortality early after myocardial infarction (MI). This study investigated the vascular effects of mineralocorticoid receptor blockade in the early phase postinfarction in rats. Starting immediately after coronary ligation, male Wistar rats were treated with placebo or eplerenone (100 mg/kg/d). After 7 days, hemodynamic assessment was performed and endothelial function was determined. Maximum acetylcholine-induced relaxation was significantly attenuated in aortic rings from rats with heart failure after MI, and ameliorated by eplerenone treatment. Endothelium-independent relaxation by DEA-NONOate was similar among the groups. Endothelial NO synthase phosphorylation was reduced in the aorta of MI rats and restored by eplerenone therapy. Angiotensin I-induced vasoconstriction as well as angiotensin-converting enzyme protein levels were enhanced in aortas from MI placebo rats, and reduced by mineralocorticoid receptor inhibition. Aortic reactive oxygen species formation as well as the expression of the NAD(P)H oxidase subunit p22phox were increased after MI and normalized in eplerenone treated rats. In conclusion, mineralocorticoid receptor antagonism improved endothelial dysfunction in the early phase post-MI. Underlying mechanisms involve inhibition of vascular angiotensin-converting enzyme upregulation and improvement of endothelial NO synthase-derived NO bioavailability.


Key Words: aldosterone • acute myocardial infarction • endothelial dysfunction • oxidative stress


Related Article:

Avoiding Vicious Circles: Mineralocorticoid Receptor Antagonism Prevents Vascular Oxidative Stress Early After Myocardial Infarction
Ralf P. Brandes
Hypertension 2007 50: 842-843. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Eur Heart JHome page
P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, et al.
Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone
Eur. Heart J., September 1, 2008; 29(17): 2171 - 2179.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. Fraccarollo, P. Galuppo, S. Schraut, S. Kneitz, N. van Rooijen, G. Ertl, and J. Bauersachs
Immediate Mineralocorticoid Receptor Blockade Improves Myocardial Infarct Healing by Modulation of the Inflammatory Response
Hypertension, April 1, 2008; 51(4): 905 - 914.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Yu, S.-G. Wei, Z.-H. Zhang, E. Gomez-Sanchez, R. M. Weiss, and R. B. Felder
Does Aldosterone Upregulate the Brain Renin-Angiotensin System in Rats With Heart Failure?
Hypertension, March 1, 2008; 51(3): 727 - 733.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. Bauersachs and D. Fraccarollo
More NO-No More ROS: Combined Selective Mineralocorticoid Receptor Blockade and Angiotensin-Converting Enzyme Inhibition for Vascular Protection
Hypertension, March 1, 2008; 51(3): 624 - 625.
[Full Text] [PDF]


Home page
HypertensionHome page
R. P. Brandes
Avoiding Vicious Circles: Mineralocorticoid Receptor Antagonism Prevents Vascular Oxidative Stress Early After Myocardial Infarction
Hypertension, November 1, 2007; 50(5): 842 - 843.
[Full Text] [PDF]